Zavaglia Claudio, De Carlis Luciano, Alberti Alberto Battista, Minola Ernesto, Belli Luca Saverio, Slim Abdallah Omar, Airoldi Aldo, Giacomoni Alessandro, Rondinara Gianfranco, Tinelli Carmine, Forti Domenico, Pinzello Giovambattista
Struttura Complessa di Gastroenterologia ed Epatologia "Crespi,", Ospedale Niguarda, Milano.
Am J Gastroenterol. 2005 Dec;100(12):2708-16. doi: 10.1111/j.1572-0241.2005.00289.x.
The aim of this study was to identify predictors of both survival and tumor-free survival of a cohort of 155 patients, with hepatocellular carcinoma (HCC) and cirrhosis, who were treated by orthotopic liver transplantation (OLT).
From January 1989 to December 2002, 603 OLTs were performed in 549 patients. HCC was diagnosed in 116 patients before OLT and in 39 at histological examination of the explanted livers. Eighty-four percent of the patients met "Milan" criteria at histology. Ninety-four patients received anticancer therapies preoperatively.
The median follow-up was 49 months (range, 0-178). Overall, 1-, 3-, 5-, and 10-yr survival were 84%, 75%, 72%, and 62%, respectively. Survival was not affected by the patient's age or sex, etiology of liver disease, Child score at transplantation, rejection episodes, tumor number, total tumor burden, bilobar tumor, and pathologic Tumor, Nodes, Metastasis (pTNM) stages. There was no statistically significant difference in survival when patients were grouped according to the recently proposed simplified pTNM staging (5-yr survival, 80% in stage I, 69% in stage II, 50% in stage III, p= 0.3) or the United Network for Organ Sharing (UNOS) staging system for HCC. Encapsulation of the tumor and alpha-fetoprotein levels significantly affect patient survival. Five-year survival of patients with poorly differentiated (G3) HCC was significantly worse than that of patients with moderately (G2) or well-differentiated (G1) HCC (respectively, G3 44%, G2 67%, and G1 97%, p= 0.0015). Patients with micro- or macro-vascular invasion had a worse 5-yr survival than patients without vascular invasion (49%vs 77%, p= 0.04). Multivariate analysis showed that histological grade of differentiation and macroscopic vascular invasion are independent predictors of survival (HR 2.4, 95% CI 1.4-4.1, p= 0.0009 and HR 2.8, 95% CI 1.2-6.8, p= 0.022).
Histological grade of differentiation and macroscopic vascular invasion, as assessed on the explanted livers, are strong predictors of both survival and tumor recurrence in patients with cirrhosis who received transplants for HCC.
本研究旨在确定155例接受原位肝移植(OLT)治疗的肝细胞癌(HCC)合并肝硬化患者的生存及无瘤生存预测因素。
1989年1月至2002年12月,对549例患者实施了603例OLT。116例患者在OLT前被诊断为HCC,39例在移植肝组织学检查时被诊断为HCC。84%的患者组织学符合“米兰”标准。94例患者术前接受了抗癌治疗。
中位随访时间为49个月(范围0 - 178个月)。总体而言,1年、3年、5年和10年生存率分别为84%、75%、72%和62%。患者的年龄、性别、肝病病因、移植时的Child评分、排斥反应、肿瘤数量、总肿瘤负荷、双侧肿瘤以及病理肿瘤、淋巴结、转移(pTNM)分期均不影响生存。根据最近提出的简化pTNM分期(5年生存率:I期80%,II期69%,III期50%,p = 0.3)或器官共享联合网络(UNOS)的HCC分期系统对患者进行分组时,生存率无统计学显著差异。肿瘤包膜及甲胎蛋白水平显著影响患者生存。低分化(G3)HCC患者的5年生存率显著低于中分化(G2)或高分化(G1)HCC患者(分别为:G3 44%,G2 67%,G1 97%,p = 0.0015)。有微血管或大血管侵犯的患者5年生存率低于无血管侵犯的患者(49%对77%,p = 0.04)。多因素分析显示,组织学分化程度和宏观血管侵犯是生存的独立预测因素(HR 2.4,95%CI 1.4 - 4.1,p = 0.0009;HR 2.8,95%CI 1.2 - 6.8,p = 0.022)。
移植肝组织学评估的组织学分化程度和宏观血管侵犯是接受HCC移植的肝硬化患者生存及肿瘤复发的有力预测因素。